Nov. 3, 2008-Orion Corporation has been informed that an Abbreviated New Drug Application (ANDA) has been filed by Wockhardt Limited (Wockhardt) with the U.S. Food and Drug Administration (FDA) seeking authorisation to produce and market a generic version of Stalevo® (specifically 12.5/200/50 mg strength of carbidopa/entacapone/levodopa) in the United States.
The details can be read here.
No comments:
Post a Comment